Catharina Braren-Von Stülpnagel

Catharina Braren-Von Stülpnagel

Auto-generated profile, based on publicly available information

Catharina Braren-Von Stülpnagel

Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
CSC.C. von Stülpnagel
C.C. von Stülpnagel
MAM. Augustin
M. Augustin
LDL. Düpmann
L. Düpmann
NBNeuza da Silva Burger
Neuza da Silva Burger
RSR. Sommer
R. Sommer
Patients with chronic skin diseases suffer from physical and psychosocial impairments which can lead to a cumulative life‐long burden. Therefore, the concept of cumulative life course impairment (CLCI) was introduced, referring to the non‐reversible damage due to the persistent life‐long burden. This systematic review (PROSPERO registry number: CRD42020179141) aimed at mapping the risk factors and the associated burden over time in patients with psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS). Three electronic databases were searched (date of the last search: December 2019). Studies with a longitudinal study design that assessed the association between a risk factor and the associated burden over time in patients with psoriasis, AD and HS were included. Quality assessment of the included studies was done using Critical Appraisal Skills Programme (CASP) checklists. In total, 40 publications reflecting 25 different studies were included: nine studies addressed patients with psoriasis, 13 patients with AD, two studies included patients with HS and one study enrolled patients with psoriasis and AD, respectively. Twenty‐two potential risk factors with underlying evidence were found in this review. These risk factors include mainly sociodemographic (such as age or gender) and clinical (such as disease severity or comorbidities) variables. Disease severity and comorbidities were the most often studied risk factors, while only a few studies evaluated psychosocial risk factors over time. Patients with chronic skin diseases are at high risk to develop a life‐long negative impact from the disease. However, there is a lack of data that evaluates the psychosocial burden and its influence on the patients’ life course over time. The risk factors found in this review help to identify patients at risk, to treat them adequately and, ultimately, to prevent CLCI. These results can be the basis to develop a highly needed tool to assess the risk for CLCI in the future.

17 February 2021 in Wound Repair and Regeneration
Verified
Journal Article
Open access
PDF file
CSCatharina C. von Stülpnagel
Catharina C. von Stülpnagel
NSNeuza da Silva
Neuza da Silva
MAMatthias Augustin
Matthias Augustin
CMCatherine van Montfrans
Catherine van Montfrans
CFCaroline Fife
Caroline Fife
RSRachel Sommer
Rachel Sommer
The Wound‐QoL is an often used reliable and valid measure, originally developed in Germany. It has been sequentially translated and validated for other languages/countries, for the measurement of health‐related quality of life (HRQoL) in patients with chronic wounds. However, a study from the United States postulated its benefits from further adaptations. Furthermore, some patients struggled to provide an answer for some of the items. We aimed to test the cross‐cultural structure and psychometric performance of the questionnaire to suggest necessary revisions. This cross‐sectional analysis of existing data sets included 1185 patients from Germany, the US, the Netherlands, Spain, Sweden, and Israel. Patients in the U.S. Wound Registry completed the Wound‐QoL during routine care. Different studies comprised the data collection in the other countries. Almost half of the patients were women (48.4%). Furthermore, 42.6% were diagnosed with leg ulcers. Their average age was 66 years. We used a confirmatory factor analysis and an unconstrained graded response model. We revised and shortened the Wound‐QoL from 17 to 14 items. In addition, we supported the cross‐cultural metric invariance of the revised Wound‐QoL questionnaire. The new version with 14 items and three dimensions revealed good psychometric properties with Cronbach's alpha (α) of 0.913 for the total score, and 0.709–0.907 for different dimensions. Furthermore, we provided strict invariance for different clinical variables. In conclusion, the revised Wound‐QoL is a reliable and cross‐cultural instrument to measure the HRQoL on patients with chronic wounds. Future studies should analyse the revised Wound‐QoL for convergent validity with generic HRQoL questionnaires as well as for determining its sensitivity to clinical change.

25 February 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
RSR. Sommer
R. Sommer
MAM. Augustin
M. Augustin
CHC. Hilbring
C. Hilbring
SSS. Ständer
S. Ständer
MHM. Hubo
M. Hubo
NBNeuza da Silva Burger
Neuza da Silva Burger
Background: 60–90% of patients with psoriasis suffer from pruritus and 65% report itching as one of the most burdensome symptoms, raising significant quality of life (QoL) impairments. However, pruritus is not only an intrapersonal symptom but also a psychosocial interactive phenomenon and little is known about the effects of itching on interpersonal experiences.Objectives: This study aimed to compare the disease burden and patient needs between patients with none/mild vs. moderate/severe pruritus, and to examine the impact of disease parameters and intrapersonal burden on perceived stigmatization and sexual relationships.Methods: This cross‐sectional study included German patients aged ≥ 18 years with psoriasis vulgaris. Disease severity was assessed with Psoriasis Area and Severity Index; patients reported on intensity of pruritus, skin‐generic and pruritus‐specific QoL, patient needs and benefits, anxiety and depression symptoms, dysmorphic concerns, perceived stigmatization and sexual dysfunction.Results: A total of 107 patients with psoriasis participated (mean age = 46.3 ± 14.6 years; 52.3% male): 64 with none/mild pruritus (NRS ≤ 3) and 43 with moderate/severe pruritus (NRS ≥ 4). Patients with moderate/severe pruritus reported more QoL impairments, depression and anxiety symptoms and dysmorphic concerns, but less treatment benefits, than those with none/mild pruritus. The patient needs most frequently rated as ‘very/quite important’ were ‘be healed of all skin defects’ (88.8%), and ‘be free of itching’ (87.0%), with no differences between the groups. Younger age, disease severity, frequency of scratching behaviours, dysmorphic concerns and treatment benefits were positively associated with stigmatization experiences; disease severity, sleeping problems and skin‐generic QoL impairments were positively associated with sexual dysfunction.Conclusions: Pruritus induces significant burden in patients with psoriasis. Along with disease severity, intrapersonal burden has a great impact on social and dyadic relationships. Treatment choices that are effective in reducing pruritus should be prioritized in patient‐centred healthcare.

23 September 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
NBNeuza da Silva Burger
Neuza da Silva Burger
MAMatthias Augustin
Matthias Augustin
CHCaroline Hilbring
Caroline Hilbring
CSCatharina C Braren-Von Stülpnagel
Catharina C Braren-Von Stülpnagel
RSRachel Sommer
Rachel Sommer
Objectives While stress plays a paramount role on the onset/exacerbation of psoriasis, via overactivation of the hypothalamic–pituitary–adrenal axis and increased release of pro-inflammatory cytokines, cutaneous inflammatory response induces, in turn, anxiety/depression symptoms, via body disfigurement and stigmatisation. The intensity of pruritus and anogenital involvement are additional risk factors for psychological comorbidity.Aims were to (1) examine the effects of intensity of pruritus and anogenital psoriasis on disease burden and psychological comorbidity and (2) identify the variables associated with the presence of clinically significant depression, anxiety, and dysmorphic concerns. Design Cross-sectional study. Setting Conducted at the University Medical Center Hamburg-Eppendorf (UKE). Participants 107 patients with psoriasis (mean age = 46.3, SD = 14.6 years; 53.3% male): 64 with none/mild pruritus; 43 with moderate/severe pruritus; 31 with anogenital psoriasis; 76 not affected in the anogenital area. Primary/secondary outcomes measures Disease severity was assessed with Psoriasis Area and Severity Index and intensity of pruritus was rated by patients. Patient-reported outcomes included the Dermatology Life Quality Index, ItchyQoL, Patient Benefit Index, Perceived Stigmatisation Questionnaire, and Relationship and Sexuality Scale. Psychological morbidity was assessed with the Patient Health Questionnaire, Generalised Anxiety Disorder, and Dysmorphic Concern Questionnaire. Results Patients with moderate/severe pruritus reported more quality of life impairments, depression, anxiety and dysmorphic concerns, and less treatment benefits than those with none/mild pruritus. Moderate/severe pruritus had a deleterious effect on depression and stigmatisation for patients without anogenital involvement. Less patient benefits were associated with a higher likelihood of clinically significant depression/anxiety. Conclusion Pruritus induces significant burden and psychological morbidity, particularly for patients without anogenital involvement. However, coping strategies used by patients with anogenital psoriasis might be dysfunctional for overall psychosocial adaptation. Patient-centred healthcare might be the best way to prevent psychological comorbidity. Ethics approval Ethics Committee of the Medical Association of Hamburg (process number PV6083, 28 May 2019).

13 March 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
CSCatharina C. Braren‐Von Stülpnagel
Catharina C. Braren‐Von Stülpnagel
MAMatthias Augustin
Matthias Augustin
LWLukas Westphal
Lukas Westphal
RSRachel Sommer
Rachel Sommer
IntroductionPatients with chronic skin diseases suffer from physical, psychological, emotional and social impairments. The overall burden has significant impact on patients' life, contributing to irreversible damage across many domains, known as cumulative life course impairment (CLCI). The aim of this project was to develop instruments which (a) measure persisting CLCI and (b) identify patients at risk for developing future CLCI. MethodsWe identified key topics that negatively impact life course due to skin disease patient-reported open item selection. Subsequently, we conducted focus group interviews with patients and experts to conceptualize items and response scales, resulting in two preliminary measurement tools. These tools were tested in a cognitive debriefing before finalization. ResultsConsecutively, 162 patients participated in the open item selection and indicated the following topics were most relevant to their disease: disease symptoms, risk behaviour, comorbidities, psychological and emotional impairments, physical impairments, occupational impairments, treatment, sexuality, problems with family or friends, everyday life and positive event or decisions because of the disease. In the focus group interviews, patients reported stigmatization, support at disease onset, pre-existing diseases and age of onset as additional important topics. The cognitive debriefing resulted in minor changes to sentence structure. The final tools included: (1) DermCLCI-r, which assesses retrospective CLCI, and (2) DermCLCI-p, which assesses current CLCI and future risk. Each tool consisted of 30 items. DiscussionThe newly developed measures allow for early identification of CLCI, facilitate adequate dermatological and psychosocial interventions and may contribute to the prevention of CLCI. Further validation studies will be performed.

21 September 2021 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
CSCatharina C. von Stülpnagel
Catharina C. von Stülpnagel
MAMatthias Augustin
Matthias Augustin
NBNeuza da Silva Burger
Neuza da Silva Burger
LSLaura Schmidt
Laura Schmidt
GNGesa Nippel
Gesa Nippel
RSRachel Sommer
Rachel Sommer
Xerosis cutis is recognized as a burdensome and stressful condition of the skin, resulting in impaired health-related quality of life (HRQoL). Therefore, it should be treated as a relevant skin dis...